全文获取类型
收费全文 | 648篇 |
免费 | 50篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 21篇 |
妇产科学 | 25篇 |
基础医学 | 84篇 |
口腔科学 | 58篇 |
临床医学 | 83篇 |
内科学 | 121篇 |
皮肤病学 | 6篇 |
神经病学 | 36篇 |
特种医学 | 15篇 |
外科学 | 88篇 |
综合类 | 3篇 |
预防医学 | 54篇 |
眼科学 | 1篇 |
药学 | 28篇 |
中国医学 | 1篇 |
肿瘤学 | 70篇 |
出版年
2023年 | 7篇 |
2022年 | 4篇 |
2021年 | 13篇 |
2020年 | 21篇 |
2019年 | 19篇 |
2018年 | 9篇 |
2017年 | 16篇 |
2016年 | 21篇 |
2015年 | 13篇 |
2014年 | 28篇 |
2013年 | 30篇 |
2012年 | 42篇 |
2011年 | 38篇 |
2010年 | 27篇 |
2009年 | 21篇 |
2008年 | 33篇 |
2007年 | 36篇 |
2006年 | 32篇 |
2005年 | 31篇 |
2004年 | 25篇 |
2003年 | 21篇 |
2002年 | 31篇 |
2001年 | 10篇 |
2000年 | 8篇 |
1999年 | 9篇 |
1998年 | 5篇 |
1997年 | 5篇 |
1996年 | 3篇 |
1995年 | 7篇 |
1994年 | 8篇 |
1993年 | 4篇 |
1992年 | 17篇 |
1991年 | 10篇 |
1990年 | 7篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 8篇 |
1986年 | 9篇 |
1985年 | 4篇 |
1983年 | 3篇 |
1979年 | 7篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1976年 | 3篇 |
1974年 | 3篇 |
1973年 | 3篇 |
1970年 | 3篇 |
1969年 | 2篇 |
1968年 | 4篇 |
1966年 | 3篇 |
排序方式: 共有698条查询结果,搜索用时 15 毫秒
1.
2.
Clara cell secretory protein deficiency alters clara cell secretory apparatus and the protein composition of airway lining fluid 总被引:2,自引:0,他引:2
Stripp BR Reynolds SD Boe IM Lund J Power JH Coppens JT Wong V Reynolds PR Plopper CG 《American journal of respiratory cell and molecular biology》2002,27(2):170-178
Clara cells represent the predominant secretory cell within distal conducting airways of mammals and exhibit functional alterations with chronic lung disease. We previously demonstrated that Clara cell secretory protein (CCSP) deficiency results in enhanced susceptibility to environmental agents. The present study was undertaken to define changes in Clara cell secretory function associated with CCSP deficiency in knockout mice. Comparative morphometry of Clara cell ultrastructure revealed dramatic alterations in secretory apparatus between wild-type (WT) and CCSP knockout (CCSP-/-) mice. Secretory granules, which occupy greater than 2% of Clara cell cytoplasmic volume in WT mice, were completely absent among Clara cells of CCSP-/- mice. Moreover, Clara cells of CCSP-/- mice exhibited a > 95% reduction in rough endoplasmic reticulum and alterations to Golgi apparatus, relative to WT controls. Ultrastructural perturbations to Clara cells were associated with altered protein composition of airway lining fluid as revealed by two-dimensional gel analysis of bronchoalveolar lavage proteins, but were not associated with altered abundance or secretion of CC26, another Clara cell secretory protein. We conclude that CCSP is required for the appearance of Clara cell secretory granules and that functional changes to Clara cells that result from CCSP deficiency lead to alterations in the composition of epithelial lining fluid. 相似文献
3.
In order to assess patients' preferences for different inhalation devices a questionnaire has been developed. The questionnaire consisted of items covering various aspects considered important for patients who regularly use inhalation devices. The questions were designed to be of a general character so any inhalation device could be evaluated. We evaluated the questionnaire in a multicenter, open crossover study comparing patients' opinions of MDI with and without spacer and of a dry powder inhaler, Turbuhaler. One hundred twenty-three patients with stable asthma confirmed by daily peak expiratory flow rate (PEF) measurements used for 2 weeks MDI only and MDI with spacer and for 2 weeks Turbuhaler. The order was randomized. The drugs were terbutaline inhaled via MDI and Turbuhaler and budesonide inhaled via MDI with spacer and turbuhaler. At the end of each evaluation period the patients answered a number of questions about their opinion by marking on a visual analogue scale. A factor analysis revealed that the different questions represent a few common factors important for evaluating opinion about inhalation devices. These factors are handling of the device, use, time to learn how to use the device properly, how confident the patients feel about the use of it, and taste/irritation. A standardized questionnaire of reduced size seems to be a suitable method for evaluating patient preference for different inhalation devices. 相似文献
4.
5.
6.
Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer 总被引:2,自引:0,他引:2
Preben Jakobsen Eva Steiness Lars Bastholt Mads Dalmark Anders Lorenzen Dorthe Petersen Susanne B. Gjedde Erik Sandberg Carsten Rose Ole S. Nielsen Henning T. Mouridsen Anders Jakobsen 《Cancer chemotherapy and pharmacology》1991,28(1):63-68
Summary Pharmacokinetic analysis of epirubicin and its metabolites epirubicinol and 7-deoxy-13-dihydro-epirubicinol aglycone during the first and the fourth courses of treatment was performed in 78 patients with metastatic breast cancer. The patients were treated every 3 weeks with epirubicin given as 10-min i.v. infusions at four different dose levels: 40, 60, 90 and 135 mg/m2. In most cases (76 of 78 cases), plasma concentration-time curves fitted to a three-compartmental pharmacokinetic model. The terminal half-life of epirubicin was independent of dose and duration of treatment. Large interindividual differences were demonstrated (meant
1/2, 21.6±7.9 h; range, 10.6–69 h;n=110). In two subjects, extremely long half-lives and high serum bilirubin concentrations indicated impaired liver function. No correlation was found between the half-life and levels of liver alanine aminotransferase (ALAT) or serum creatinine. The metabolite epirubicinol appeared quickly after epirubicin administration and its half-lives were shorter than that of the parent compound (meant
1/2, 18.1±4.8 h; range, 8.2–38.4 h;n=105).Formation of the aglycone metabolite was delayed and the half-life of this metabolite was shorter than that of epirubicin (meant
1/2, 13±4.6 h; range, 2.7–29 h;n=104). The AUC of epirubicin and the total AUC (drug and metabolites) were linearly proportional to the dose, with the former value constituting two-thirds of the latter. A correlation was found between AUC and the plasma concentration of epirubicin at two time points (2 and 24 h after administration). The proposed model was AUC=9.44×c
2+62.5×c
24+157.7 (r=0.953).This work was supported by the Lundbeck Foundation, the Michaelsen Foundation and Farmitalia Carlo Erba Ltd. 相似文献
7.
8.
9.
10.